Medexus Pharmaceuticals has obtained exclusive Canadian rights to UM171 Cell Therapy (Zemcelpro®), a novel stem cell transplant product conditionally approved in Europe for treating blood cancers. The therapy, developed in Canada, is expected to launch commercially in Canada by 2028 or later, pending Health Canada approval. This deal strengthens Medexus's hemato-oncology portfolio and aims to address significant patient needs in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Medexus plans to submit for Canadian regulatory approval soon and may offer access through special programs before full approval.
Utility stocks Edison International and PG&E Corporation fell sharply after California lawmakers passed wildfire legislation without expected liability protections, exposing utilities to costly claims. Edison dropped over 23%, nearing its 52-week low...
Several stocks saw significant gains due to recent financing disclosures, new analyst coverage, and leadership appointments. Antelope Enterprise Holdings rose 83% after raising nearly $19 million in a private placement. Ticketplus jumped 31% followin...
Bitwise's XRP ETF has crossed $500 million in assets under management just nine months after its November 2025 launch. The fund holds nearly 364.8 million XRP, allowing investors to gain exposure to the cryptocurrency indirectly through brokerage acc...
TXNM Energy announced a public offering of 7,079,646 common shares priced at $56.50 each, aiming to raise approximately $400 million before expenses. The company plans to use the proceeds to repay borrowings under its $400 million term loan agreement...
Apple has filed new evidence in its lawsuit claiming former employee Chang Liu stole confidential trade secrets to benefit OpenAI. The evidence includes use of a secret Apple circuit schematic and an internal tool name in Liu's work at OpenAI. Apple ...
